Latest Breaking News On - Abelson tyrosine - Page 1 : comparemela.com

Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity

Company to host conference call on Thursday, May 16, 2024 at 8:00 a.m. ETBOSTON and ATLANTA, May 15, 2024 Inhibikase Therapeutics, Inc. , a clinical-stage pharmaceutical company developing.

United statesAlex loboMiltonh wernerOffice of cardiologyDivision of cardiologySternir incCompany contactSteam reviewExchange commissionInhibikase or companyDivision of hematologic malignanciesInhibikase therapeutics incAbelson tyrosine kinasesChief executive officerUpcoming milestonesMeeting minutes

Inhibikase Therapeutics Reports First Quarter Financial

Company to host conference call on Thursday, May 16, 2024 at 8:00 a.m. ET.

United statesMiltonh wernerAlex loboInhibikase therapeutics incDivision of hematologic malignanciesInhibikase or companyExchange commissionSteam reviewCompany contactDivision of cardiologySternir incOffice of cardiologyAbelson tyrosine kinasesChief executive officerUpcoming milestonesMeeting minutes

Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement

Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesAlex loboMiltonh wernerCompany registration statement on formCompany contactInhibikase therapeutics incStern investor relations incInhibikase or companyExchange commissionAbelson tyrosine kinasesRegistration statementAbelson tyrosine kinaseAbelson tyrosineMultiple system atrophyPrivate securities litigation reform actInvestor relations

Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension

Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesMiltonh wernerMilton wernerAlex loboCompany phaseDivision of cardiologyInhibikase therapeutics incExchange commissionStern investor relations incCompany contactInhibikase or companyDrug administrationNew molecular entityPulmonary arterial hypertensionAbelson tyrosine kinasesInvestigational new drug

Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs

BOSTON and ATLANTA, April 18, 2024 Inhibikase Therapeutics, Inc. , a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson s.

United statesMiltonh wernerAlex loboInhibikase or companySternir incExchange commissionInstitute of the national institutes healthNational institute of neurological diseaseCompany contactDrug administration for ikInhibikase therapeutics incAbelson tyrosine kinasesFellow shareholdersInhibikase therapeuticsDrug administrationMultiple system atrophy